Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vernonia amygdalina is a perennial shrub or small tree belonging to the Asteraceae family, commonly known as bitter leaf due to its bitter taste. It grows in most parts of sub-Saharan Africa, particularly in tropical regions. The plant reaches heights of 2-5 meters with elliptical green leaves up to 20cm long. The leaves, stems, and bark contain various bioactive compounds including flavonoids, alkaloids, saponins, tannins, triterpenoids, sesquiterpene lactones, steroids, cardiac glycosides, and phenols. These compounds contribute to its numerous medicinal properties. Vernonia amygdalina has demonstrated multiple pharmacological activities including: - Anti-inflammatory and analgesic effects - Antioxidant properties - Antimalarial activity - Antidiabetic effects - Antibacterial and antifungal properties - Antiparasitic/anthelmintic activity - Anticancer potential Traditionally, it has been used for treating various conditions including fever, malaria, diabetes, gastrointestinal disorders, kidney problems, and as a fertility inducer in subfertile women.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on vernonia amygdalina.